Correction to: A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency

Key Points

• Pharmacokinetics and efficacy are critical for effective immune globulin treatments in patients with primary immunodeficiency.
• The correction enhances understanding of loading and maintenance dosing strategies in treatment-naïve and experienced patients.
• Observational analysis of pharmacokinetics revealed variability in response among patients, impacting efficacy and safety profiles.
• Highlighting refinements in dosing may improve treatment outcomes, necessitating further validation across diverse patient populations.